

Setting the Record

Straight

340B and Expansion

Big Pharma false narrative:



"Senate Bill 25-071 expands the 340B program."

Setting the record straight:



Senate Bill 25-071 maintains the federal status quo by prohibiting the unilateral restrictions that Big Pharma is placing on the program.

It is not an expansion.

The 340B program was established through bipartisan legislation in 1992 with strong support from both political parties. When the program was founded, Congress itself noted that the goal of the program is "to enable [covered entities] to stretch scarce Federal resources as far as possible, reaching more eligible patients and providing more comprehensive services."

Congress increased the number of qualifying entities three times: 2003, 2005, and 2010, adding:



Freestanding Cancer Hospitals



Children's Hospitals



Critical Access Hospitals



Rural Referral Centers



Sole Community Hospitals

The greatest increase in use of the 340B program was not only intentional and expected but was the direct result of Congressional action.

Big Pharma false narrative:



"Hospitals are driving unsustainable growth of the 340B program."

Setting the record straight:



Over recent years, there have been increases in several factors which all contribute to the growth of the 340B program overall:



Increase in the use of specialty drugs



Improved ability to treat patients on an outpatient basis



Rising costs of specialty drugs far outpacing inflation

By Contrast:

There is no requirement for pharmaceutical manufacturers to participate in 340B UNLESS they choose to participate in the lucrative Medicaid program. If it didn't make financial sense for them, they would not be participating in either program.

FOR MORE INFORMATION:

Contact Saskia Young, CHA VP of Legislative Affairs, at Saskia.Young@cha.com